Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER Positive, HER2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Large-scale testing (Phase 3)Active Not RecruitingNCT06065748
What this trial is testing

Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche 1,050
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07801898
What this trial is testing

Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer

Who this might be right for
Invasive Breast Cancer (Stage I-III)
The Second Hospital of Anhui Medical University 36
Not applicableUnknownNCT03790813
What this trial is testing

Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 50
Not applicableStudy completedNCT01928186
What this trial is testing

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+7 more
University of Washington 28
Testing effectiveness (Phase 2)WithdrawnNCT01658176
What this trial is testing

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer
Large-scale testing (Phase 3)Study completedNCT01101438
What this trial is testing

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 3,649
Testing effectiveness (Phase 2)Ended earlyNCT01430585
What this trial is testing

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Who this might be right for
Early Breast Cancer (Phase 2)Advanced Breast Cancer (Phase 1b)
Pfizer 14
Not applicableStudy completedNCT02773004
What this trial is testing

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 203
Not applicableUnknownNCT05559528
What this trial is testing

BRaziLian outcomE for metAStatic breasT Cancer

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IV
Hospital do Coracao 300
Large-scale testing (Phase 3)Looking for participantsNCT05901428
What this trial is testing

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Fudan University 1,736
Testing effectiveness (Phase 2)Active Not RecruitingNCT05596409
What this trial is testing

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Who this might be right for
Metastatic Breast Cancer
Stemline Therapeutics, Inc. 61
Testing effectiveness (Phase 2)Study completedNCT01105312
What this trial is testing

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 28
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Testing effectiveness (Phase 2)Looking for participantsNCT06923527
What this trial is testing

Circulating Tumor DNA

Who this might be right for
ER+ Breast Cancer
Yale University 50
Testing effectiveness (Phase 2)Study completedNCT02971761
What this trial is testing

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Who this might be right for
Androgen Receptor PositiveEstrogen Receptor NegativeHER2/Neu Negative+3 more
City of Hope Medical Center 18
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Active Not RecruitingNCT01805271
What this trial is testing

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Who this might be right for
Primary Non-metastatic Breast CancerWho Remain Disease-free
UNICANCER 1,278
Early research (Phase 1)Study completedNCT04176757
What this trial is testing

ZN-c5 in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Zeno Alpha Inc. 35
Next Page